Author: Customer Service

La Hulpe, Belgium – July 13, 2026, 07:00 CEST – INSIDE INFORMATION – Banqup Group SA, (Euronext:BANQ) (Banqup, Company) announces that it has entered into an incremental facility notice under itsexisting Senior Facilities Agreement dated 7 March 2022 (as amended) with funds affiliated with FranciscoPartners, one of its existing senior secured lenders, for an additional committed term facility of EUR 4.0million (the Incremental Facility). Facility A under the Senior Facilities Agreement now stands at EUR 4,000,000, and the Incremental Facilityprovides the Company with additional financial flexibility to support the Group’s liquidity position pendingcompletion of the strategic review process announced by the Company. The Company’s Board of Directors has also approved the possibility of further incremental facilities of up to...

Pratteln, Switzerland, July 13, 2026 – Santhera Pharmaceuticals (SIX: SANN) today announces an expansion of its exclusive distribution agreement with Biomedica for AGAMREE® (vamorolone), extending the partnership to include Georgia, Kazakhstan, Belarus, Azerbaijan and Uzbekistan, for the treatment of Duchenne muscular dystrophy (DMD) in patients two years of age and older. Biomedica was originally appointed as a distributor for AGAMREE® in October 2025. Under the expanded agreement, Biomedica will be responsible for distribution in the additional five markets, while Santhera will continue to receive a percentage of net sales in line with the terms of the original agreement. Approximately 2,000 patients are living with DMD across these additional countries, where treatment options have historically been largely limited to standard corticosteroids....

Health Canada NOC enables treatment for porphyria, metabolic disorder MELBOURNE, Australia, July 13, 2026 (GLOBE NEWSWIRE) — CLINUVEL’s novel drug SCENESSE® (afamelanotide) has been granted a Notice of Compliance (NOC) by Health Canada for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The NOC acknowledges the compliance of the SCENESSE® new drug submission with Section C.08.002 and C.08.005 of the Canadian Food and Drug Regulations and grants CLINUVEL the right to market SCENESSE® in Canada. Commentary “Health Canada has taken a long time to arrive at this positive outcome,” said Dr Dennis Wright, CLINUVEL’s Chief Scientific Officer. “Data from our global programs – including considerable data from postmarketing experience – were used to demonstrate the safety and clinical benefit of...

Common stock begins trading on the OTCQB under the symbol “PALX” effective July 10, 2026; Company continues development of its core optical technologies focused on moving data faster and more efficiently in AI data centers GOLETA, Calif., July 13, 2026 (GLOBE NEWSWIRE) — Palomino Laboratories, Inc. (OTCQB: PALX) (“Palomino” or the “Company”), an innovator in optical interconnect technologies designed to address the rapidly increasing bandwidth and energy-efficiency requirements of artificial intelligence (AI), high-performance computing (HPC), and next-generation data centers, today announced that its common stock has begun trading on the OTCQB Venture Market under the ticker symbol “PALX.” The Company’s shares are also DTC eligible, enabling electronic clearing and settlement...

HONOLULU, July 12, 2026 (GLOBE NEWSWIRE) — First Hawaiian, Inc. (NASDAQ: FHB) announced today that it plans to release its second quarter 2026 financial results on Friday, July 24, 2026 before the market opens. First Hawaiian will host a conference call to discuss the company’s results on the same day at 1:00 p.m. Eastern Time (7:00 a.m. Hawaii Time). To access the call by phone, participants will need to click on the following registration link: https://register-conf.media-server.com/register/BIb8e318d9b8d24417b3d7d113fcf80dbc, register for the conference call, and then you will receive the dial-in number and a personalized PIN code. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. A live webcast of the conference call, including a slide presentation,...

PERTH, Australia , July 12, 2026 (GLOBE NEWSWIRE) — Paladin Energy Ltd (ASX:PDN, TSX:PDN, OTCQX:PALAF) (“Paladin” or the “Company”) advises that it will release its quarterly results for the period ended 30 June 2026 on the ASX platform on Wednesday, 22 July 2026. The announcement will also be available on the SEDAR+ platform. The Company will hold a conference call on Wednesday, 22 July 2026, at 11.00am AEST1 (Tuesday, 21 July 2026, at 9.00pm EDT2). To participate in the live teleconference, please register at the link below: Paladin June 2026 Quarterly Results Conference Call Please note it is recommended to log on at least five minutes before the scheduled commencement time to ensure you are registered in time for the start of the call. A recording of the call will be available on Paladin’s website shortly after its conclusion. This...

New clinical and real-world data support a subcutaneous treatment pathway from initiation through maintenance treatment, offering dosing convenience for patients and care partners TOKYO and CAMBRIDGE, Mass., July 12, 2026 (GLOBE NEWSWIRE) — Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that new data presented at the Alzheimer’s Association International Conference® (AAIC®) 2026 in London support that the LEQEMBI® (lecanemab) subcutaneous autoinjector (SC-AI) formulation offers efficacy and safety comparable to intravenous (IV) administration for people with early Alzheimer’s disease (AD). The data was featured during the “Lecanemab Subcutaneous Formulation in Early Alzheimer’s Disease: Emerging Clinical Evidence and Practical Use Considerations” Developing Topics Session #1-32-FRS-C. AD is a chronic, progressive...

The new data demonstrates the potential to improve control of acute infection, latency, and viral reactivation, further supporting the concept behind EVX-V1 EVX-V1 is a next-generation, multi-component vaccine program combining novel AI-discovered antigens with AI-optimized versions of established CMV vaccine antigens Data presented today in poster presentation at the International Herpesvirus Workshop 2026 taking place in Montreal, CanadaCOPENHAGEN, Denmark, July 12, 2026 – Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, presents new data further supporting the multi-component concept of its cytomegalovirus (CMV) vaccine program EVX-V1. Data is presented today in a poster session at the International Herpesvirus Workshop (IHW)...

HMB-002 clinical data demonstrate proof of mechanism, with dose-dependent, greater than or equal to 2.4-fold peak increases in Von Willebrand Factor (VWF) and Factor VIII (FVIII), normalization of peak thrombin generation and activated partial thromboplastin time (APTT), and durability supporting potential monthly subcutaneous dosing HMB-003 program announced as non-hormonal direct plasmin inhibitor with potent, selective and extended antifibrinolytic activity, designed to reduce bleeding across multiple settings beginning in heavy menstrual bleeding CAMBRIDGE, Mass. and COPENHAGEN, Denmark, July 12, 2026 (GLOBE NEWSWIRE) — Hemab Therapeutics (Nasdaq:COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience, today presented...

PASCAGOULA, Miss., July 11, 2026 (GLOBE NEWSWIRE) — HII (NYSE: HII) christened the future USS George M. Neal (DDG 131), the fourth Flight III Arleigh Burke-class destroyer to be built at the company’s Ingalls Shipbuilding division. The ship is named for Aviation Machinist’s Mate Third Class George M. Neal, a Korean War veteran and Navy Cross recipient. In 1951, Neal’s helicopter crashed during a rescue attempt in the North Korean mountains. He evaded enemy forces for nine days before being captured and held as a prisoner of war for two and a half years. He was released and returned to the United States in 1952 along with more than 320 fellow prisoners of war. Performing the duties of the under secretary of the Navy, William Toti delivered the keynote address. “The future USS George M. Neal honors a legacy of extraordinary courage...